## Maarten W Taal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6733378/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney International, 2000, 57, 1803-1817.	5.2	390
2	An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes, Obesity and Metabolism, 2020, 22, 3-15.	4.4	278
3	Progressive Vascular Calcification over 2 Years Is Associated with Arterial Stiffening and Increased Mortality in Patients with Stages 4 and 5 Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1241-1248.	4.5	267
4	Predicting initiation and progression of chronic kidney disease: Developing renal risk scores. Kidney International, 2006, 70, 1694-1705.	5.2	221
5	CKD: A Call for an Age-Adapted Definition. Journal of the American Society of Nephrology: JASN, 2019, 30, 1785-1805.	6.1	198
6	The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2021, 99, 34-47.	5.2	195
7	Vascular calcification and cardiovascular function in chronic kidney disease. Nephrology Dialysis Transplantation, 2006, 21, 707-714.	0.7	189
8	Activation of the Heart by Donor Brain Death Accelerates Acute Rejection After Transplantation. Circulation, 2000, 102, 2426-2433.	1.6	182
9	A Meta-analysis of Hemodialysis Catheter Locking Solutions in the Prevention of Catheter-Related Infection. American Journal of Kidney Diseases, 2008, 51, 233-241.	1.9	169
10	Risk factors for reduced bone density in haemodialysis patients. Nephrology Dialysis Transplantation, 1999, 14, 1922-1928.	0.7	167
11	Prevalence and associations of limited health literacy in chronic kidney disease: a systematic review. Nephrology Dialysis Transplantation, 2013, 28, 129-137.	0.7	148
12	The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. BMC Nephrology, 2015, 16, 193.	1.8	146
13	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation, 2018, 138, 1505-1514.	1.6	145
14	Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney International, 2004, 66, 801-805.	5.2	134
15	IHG-2, a Mesangial Cell Gene Induced by High Glucose, Is Human gremlin. Journal of Biological Chemistry, 2000, 275, 9901-9904.	3.4	126
16	Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR<45 mL/min/1.73 m2): a summary document from the European Renal Best Practice Group. Nephrology Dialysis Transplantation, 2017, 32, 9-16.	0.7	120
17	Reduced baroreflex sensitivity is associated with increased vascular calcification and arterial stiffness. Nephrology Dialysis Transplantation, 2005, 20, 1140-1147.	0.7	118
18	Intradialytic Cardiac Magnetic Resonance Imaging to Assess Cardiovascular Responses in a Short-Term Trial of Hemodiafiltration and Hemodialysis. Journal of the American Society of Nephrology: JASN, 2017, 28, 1269-1277.	6.1	117

#	Article	IF	CITATIONS
19	Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney International, 2000, 58, 1664-1676.	5.2	108
20	Impact of Compliance with a Care Bundle on Acute Kidney Injury Outcomes: A Prospective Observational Study. PLoS ONE, 2015, 10, e0132279.	2.5	108
21	Multi-hit nature of chronic renal disease. Current Opinion in Nephrology and Hypertension, 2000, 9, 85-97.	2.0	104
22	Acute kidney injury associated with COVID-19: A retrospective cohort study. PLoS Medicine, 2020, 17, e1003406.	8.4	99
23	Multiparametric Renal Magnetic Resonance Imaging: Validation, Interventions, and Alterations in Chronic Kidney Disease. Frontiers in Physiology, 2017, 8, 696.	2.8	96
24	Skin Autofluorescence and the Association with Renal and Cardiovascular Risk Factors in Chronic Kidney Disease Stage 3. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2356-2363.	4.5	94
25	Renal risk scores: Progress and prospects. Kidney International, 2008, 73, 1216-1219.	5.2	91
26	Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Nephrology Dialysis Transplantation, 2018, 33, ii4-ii14.	0.7	91
27	A simple care bundle for use in acute kidney injury: a propensity score-matched cohort study. Nephrology Dialysis Transplantation, 2016, 31, 1846-1854.	0.7	90
28	Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ). Nephrology Dialysis Transplantation, 2016, 31, ii1-ii66.	0.7	87
29	Vasopeptidase Inhibition Affords Greater Renoprotection than Angiotensin-Converting Enzyme Inhibition Alone. Journal of the American Society of Nephrology: JASN, 2001, 12, 2051-2059.	6.1	86
30	Venography at insertion of tunnelled internal jugular vein dialysis catheters reveals significant occult stenosis. Nephrology Dialysis Transplantation, 2004, 19, 1542-1545.	0.7	82
31	Markers of Arterial Stiffness Are Risk Factors for Progression to End-Stage Renal Disease among Patients with Chronic Kidney Disease Stages 4 and 5. Nephron Clinical Practice, 2007, 107, c177-c181.	2.3	79
32	Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney International, 2003, 63, 1116-1120.	5.2	65
33	International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney International, 2020, 98, 849-859.	5.2	65
34	Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infectious Diseases, 2012, 12, 265.	2.9	63
35	Biological variation of measured and estimated glomerular filtration rate in patients with chronicÂkidney disease. Kidney International, 2019, 96, 429-435.	5.2	63
36	Anthropomorphic Measurements That Include Central Fat Distribution Are More Closely Related with Key Risk Factors than BMI in CKD Stage 3. PLoS ONE, 2012, 7, e34699.	2.5	62

#	Article	IF	CITATIONS
37	National trends in acute kidney injury requiring dialysis in England between 1998 and 2013. Kidney International, 2015, 88, 1161-1169.	5.2	62
38	Multimorbidity in people with chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2016, 25, 465-472.	2.0	62
39	Combination ACEI and ARB therapy: additional benefit in renoprotection?. Current Opinion in Nephrology and Hypertension, 2002, 11, 377-381.	2.0	60
40	Online Conductivity Monitoring: Validation and Usefulness in a Clinical Trial of Reduced Dialysate Conductivity. ASAIO Journal, 2005, 51, 70-76.	1.6	58
41	Treatment needs and diagnosis awareness in primary care patients with chronic kidney disease. British Journal of General Practice, 2012, 62, e227-e232.	1.4	57
42	Coffee Consumption and Kidney Function: A Mendelian Randomization Study. American Journal of Kidney Diseases, 2020, 75, 753-761.	1.9	56
43	Natural History of Skeletal Muscle Mass Changes in Chronic Kidney Disease Stage 4 and 5 Patients: An Observational Study. PLoS ONE, 2013, 8, e65372.	2.5	55
44	Quantitative assessment of renal structural and functional changes in chronic kidney disease using multi-parametric magnetic resonance imaging. Nephrology Dialysis Transplantation, 2020, 35, 955-964.	0.7	54
45	Tissue-Advanced Glycation End Product Concentration in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 51-55.	4.5	53
46	Considerable international variation exists in blood pressure control and antihypertensive prescriptionÂpatterns in chronic kidney disease. Kidney International, 2019, 96, 983-994.	5.2	51
47	The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: A primary care cohort study. PLoS Medicine, 2017, 14, e1002400.	8.4	51
48	Mechanisms underlying renoprotection during renin-angiotensin system blockade. American Journal of Physiology - Renal Physiology, 2001, 280, F343-F355.	2.7	50
49	Pathogenesis of diabetic nephropathy: focus on transforming growth factor-β and connective tissue growth factor. Current Opinion in Nephrology and Hypertension, 2001, 10, 727-738.	2.0	49
50	The epidemiology of hospitalised acute kidney injury not requiring dialysis in England from 1998 to 2013: retrospective analysis of hospital episode statistics. International Journal of Clinical Practice, 2016, 70, 330-339.	1.7	47
51	Anti-CD28 Monoclonal Antibody Therapy Prevents Chronic Rejection of Renal Allografts in Rats. Journal of the American Society of Nephrology: JASN, 2002, 13, 519-527.	6.1	47
52	Suboptimal blood pressure control in chronic kidney disease stage 3: baseline data from a cohort study in primary care. BMC Family Practice, 2013, 14, 88.	2.9	45
53	Assessment of haemodialysis adequacy by ionic dialysance: intra-patient variability of delivered treatment. Nephrology Dialysis Transplantation, 2003, 18, 559-563.	0.7	44
54	Chronic Kidney Disease in Primary Care: Outcomes after Five Years in a Prospective Cohort Study. PLoS Medicine, 2016, 13, e1002128.	8.4	44

#	Article	IF	CITATIONS
55	Sodium and water handling during hemodialysis: new pathophysiologic insights and management approaches for improving outcomes in end-stage kidney disease. Kidney International, 2019, 95, 296-309.	5.2	44
56	Hypertonic glucose-based peritoneal dialysate is associated with higher blood pressure and adverse haemodynamics as compared with icodextrin. Nephrology Dialysis Transplantation, 2005, 20, 1848-1853.	0.7	43
57	Dialysis-Induced Cardiovascular and Multiorgan Morbidity. Kidney International Reports, 2020, 5, 1856-1869.	0.8	42
58	Usefulness of quantitative heel ultrasound compared with dual-energy X-ray absorptiometry in determining bone mineral density in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 1999, 14, 1917-1921.	0.7	41
59	Effects of Acetate-Free Double-Chamber Hemodiafiltration and Standard Dialysis on Systemic Hemodynamics and Troponin T Levels. ASAIO Journal, 2006, 52, 62-69.	1.6	41
60	Analysis of factors associated with variability in haemodialysis adequacy. Nephrology Dialysis Transplantation, 2004, 19, 406-412.	0.7	38
61	Cellular and molecular mediators in common pathway mechanisms of chronic renal disease progression. Current Opinion in Nephrology and Hypertension, 2000, 9, 323-331.	2.0	36
62	Determinants of Arterial Stiffness in Chronic Kidney Disease Stage 3. PLoS ONE, 2013, 8, e55444.	2.5	36
63	Patients' Experiences After CKD Diagnosis: A Meta-ethnographic Study and Systematic Review. American Journal of Kidney Diseases, 2017, 70, 656-665.	1.9	35
64	Automated Peritoneal Dialysis Has Significant Effects on Systemic Hemodynamics. Peritoneal Dialysis International, 2006, 26, 328-335.	2.3	34
65	The eGFR-C study: accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease - prospective longitudinal study in a multiethnic population. BMC Nephrology, 2014, 15, 13.	1.8	34
66	High sodium intake is associated with important risk factors in a large cohort of chronic kidney disease patients. European Journal of Clinical Nutrition, 2015, 69, 786-790.	2.9	34
67	Length of interdialytic interval influences serum calcium and phosphorus concentrations. Nephrology Dialysis Transplantation, 2005, 20, 1643-1646.	0.7	32
68	How to measure proteinuria?. Current Opinion in Nephrology and Hypertension, 2008, 17, 600-603.	2.0	32
69	Skin Autofluorescence and All-Cause Mortality in Stage 3 CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1361-1368.	4.5	31
70	Arterial stiffness in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2014, 23, 169-173.	2.0	31
71	Tissue Advanced Glycation End Product Deposition after Kidney Transplantation. Nephron Clinical Practice, 2013, 124, 54-59.	2.3	29
72	Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25Âmg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials, 2014, 15, 160.	1.6	29

#	Article	IF	CITATIONS
73	Slowing the Progression of Adult Chronic Kidney Disease. Drugs, 2004, 64, 2273-2289.	10.9	27
74	Exploration of Chronic Kidney Disease Prevalence Estimates Using New Measures of Kidney Function in the Health Survey for England. PLoS ONE, 2015, 10, e0118676.	2.5	27
75	Renal mass: An important determinant of late allograft outcome. Transplantation Reviews, 1998, 12, 74-84.	2.9	25
76	Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3. BMJ Open, 2017, 7, e016528.	1.9	25
77	The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease. Kidney International, 2014, 86, 407-413.	5.2	24
78	Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data. Nephrology Dialysis Transplantation, 2017, 32, gfw321.	0.7	24
79	Comparison of Progressive Conductivity Reduction with Diacontrol and Standard Dialysis. ASAIO Journal, 2007, 53, 194-200.	1.6	23
80	Summary of the 5th Edition of the Renal Association Clinical Practice Guidelines (2009–2012). Nephron Clinical Practice, 2011, 118, c27-c70.	2.3	23
81	Epidemiology and causes of chronic kidney disease. Medicine, 2011, 39, 402-406.	0.4	23
82	Renal Association Clinical Practice Guideline on Detection, Monitoring and Management of Patients with CKD. Nephron Clinical Practice, 2011, 118, c71-c100.	2.3	23
83	Risk Profile in Chronic Kidney Disease Stage 3: Older versus Younger Patients. Nephron Clinical Practice, 2011, 119, c269-c276.	2.3	23
84	Epidemiology and aetiology of dialysis-treated end-stage kidney disease in Libya. BMC Nephrology, 2012, 13, 33.	1.8	23
85	Prevalence of chronic kidney disease in adults in England: comparison of nationally representative cross-sectional surveys from 2003 to 2016. BMJ Open, 2020, 10, e038423.	1.9	23
86	International Criteria for Acute Kidney Injury: Advantages and Remaining Challenges. PLoS Medicine, 2016, 13, e1002122.	8.4	23
87	Demographic Associations of High Estimated Sodium Intake and Frequency of Consumption of High-Sodium Foods in People With Chronic Kidney Disease Stage 3 in England. , 2014, 24, 236-242.		22
88	Randomized Trial—PrEscription of intraDialytic exercise to improve quAlity of Life in Patients Receiving Hemodialysis. Kidney International Reports, 2021, 6, 2159-2170.	0.8	22
89	Epidemiology and causes of chronic kidney disease. Medicine, 2015, 43, 450-453.	0.4	21
90	Long-term outcomes after AKl—a major unmet clinical need. Kidney International, 2019, 95, 21-23.	5.2	20

#	Article	IF	CITATIONS
91	The association of skin autofluorescence with cardiovascular events and all-cause mortality in persons with chronic kidney disease stage 3: A prospective cohort study. PLoS Medicine, 2020, 17, e1003163.	8.4	19
92	Exercise programme to improve quality of life for patients with end-stage kidney disease receiving haemodialysis: the PEDAL RCT. Health Technology Assessment, 2021, 25, 1-52.	2.8	19
93	Use of Online Conductivity Monitoring to Study Sodium Mass Balance in Chronic Haemodialysis Patients: Prospects for Treatment Individualisation. Kidney and Blood Pressure Research, 2011, 34, 439-446.	2.0	18
94	Hemoglobin Variability with Epoetin Beta and Continuous Erythropoietin Receptor Activator in Patients on Peritoneal Dialysis. Peritoneal Dialysis International, 2012, 32, 177-182.	2.3	18
95	Development of a Formula for Estimation of Sodium Intake from Spot Urine in People with Chronic Kidney Disease. Nephron Clinical Practice, 2014, 128, 61-66.	2.3	18
96	Activation of proinflammatory mediators in heart transplants from brain-dead donors: evidence from a model of chronic rat cardiac allograft rejection. Transplantation Proceedings, 2002, 34, 2359-2360.	0.6	17
97	The Association of Nutritional Factors and Skin Autofluorescence in Persons Receiving Hemodialysis. , 2019, 29, 149-155.		17
98	Health-related quality of life, functional impairment and comorbidity in people with mild-to-moderate chronic kidney disease: a cross-sectional study. BMJ Open, 2020, 10, e040286.	1.9	15
99	Automated peritoneal dialysis has significant effects on systemic hemodynamics. Peritoneal Dialysis International, 2006, 26, 328-35.	2.3	15
100	Angiotensin-converting enzyme gene polymorphisms in renal disease: clinically relevant?. Current Opinion in Nephrology and Hypertension, 2000, 9, 651-657.	2.0	14
101	Chronic kidney disease: towards a risk-based approach. Clinical Medicine, 2016, 16, s117-s120.	1.9	14
102	Sodium MRI. Current Opinion in Nephrology and Hypertension, 2017, 26, 435-441.	2.0	14
103	Epidemiology and causes of chronic kidney disease. Medicine, 2019, 47, 562-566.	0.4	14
104	Skin autofluorescence. Current Opinion in Nephrology and Hypertension, 2019, 28, 507-512.	2.0	14
105	Evolving strategies for renoprotection: non-diabetic chronic renal disease. Current Opinion in Nephrology and Hypertension, 2001, 10, 523-531.	2.0	13
106	Achieving maximal renal protection in nondiabetic chronic renal disease. American Journal of Kidney Diseases, 2001, 38, 1365-1371.	1.9	13
107	Patients' and kidney care team's perspectives of treatment burden and capacity in older people with chronic kidney disease: a qualitative study. BMJ Open, 2020, 10, e042548.	1.9	13
108	Predicting Renal Risk in the General Population. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1523-1525.	4.5	12

#	Article	IF	CITATIONS
109	Long Term Outcomes after Acute Kidney Injury: Lessons from the ARID Study. Nephron, 2015, 131, 102-106.	1.8	12
110	The Association of Serum Free Light Chains With Mortality and Progression to End-Stage Renal Disease in Chronic Kidney Disease: Systematic Review and Individual Patient Data Meta-analysis. Mayo Clinic Proceedings, 2017, 92, 1671-1681.	3.0	12
111	Peritoneal Ultrafiltration for Heart Failure: Lessons from a Randomized Controlled Trial. Peritoneal Dialysis International, 2019, 39, 486-489.	2.3	12
112	The Association between Polyclonal Combined Serum Free Light Chain Concentration and Mortality in Individuals with Early Chronic Kidney Disease. PLoS ONE, 2015, 10, e0129980.	2.5	12
113	Defining renal risk. Current Opinion in Nephrology and Hypertension, 2007, 16, 554-556.	2.0	11
114	Screening for Chronic Kidney Disease: Preventing Harm or Harming the Healthy?. PLoS Medicine, 2012, 9, e1001345.	8.4	11
115	Reduction in sodium intake is independently associated with improved blood pressure control in people with chronic kidney disease in primary care. British Journal of Nutrition, 2015, 114, 936-942.	2.3	11
116	Adherence of tunnelled haemodialysis catheter to superior vena caval stent: successful percutaneous removal. Nephrology Dialysis Transplantation, 2003, 18, 432-433.	0.7	10
117	A Feasibility Study of Non-Invasive Continuous Estimation of Brachial Pressure Derived From Arterial and Venous Lines During Dialysis. IEEE Journal of Translational Engineering in Health and Medicine, 2021, 9, 1-9.	3.7	10
118	The PrEscription of intraDialytic exercise to improve quAlity of Life in patients with chronic kidney disease trial: study design and baseline data for a multicentre randomized controlled trial. CKJ: Clinical Kidney Journal, 2021, 14, 1345-1355.	2.9	10
119	Online measurement of haemoglobin concentration. Nephrology Dialysis Transplantation, 2005, 20, 1951-1955.	0.7	9
120	Assessment of Proteinuria in Patients with Chronic Kidney Disease Stage 3: Albuminuria and Non-Albumin Proteinuria. PLoS ONE, 2014, 9, e98261.	2.5	9
121	Prospective study of gentamicin locking of tunnelled dialysis catheters: The effect on infection rates and CRP. Kidney International, 2005, 67, 378.	5.2	8
122	Socio-Economic Disparities in the Distribution of Cardiovascular Risk in Chronic Kidney Disease Stage 3. Nephron Clinical Practice, 2013, 122, 58-65.	2.3	8
123	Feasibility and effectiveness of preâ€emptive rehabilitation in persons approaching dialysis (PREHAB). Journal of Renal Care, 2019, 45, 9-19.	1.2	8
124	Skin autofluorescence and malnutrition as predictors of mortality in persons receiving dialysis: a prospective cohort study. Journal of Human Nutrition and Dietetics, 2020, 33, 852-861.	2.5	8
125	Factors Associated With Change in Skin Autofluorescence, a Measure of Advanced Glycation End Products, in Persons Receiving Dialysis. Kidney International Reports, 2020, 5, 654-662.	0.8	8
126	Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease. Trials, 2022, 23, 331.	1.6	8

#	Article	IF	CITATIONS
127	Preventing catheter related infections in haemodialysis patients. Current Opinion in Nephrology and Hypertension, 2006, 15, 599-602.	2.0	7
128	Continuous online monitoring of ionic dialysance allows modification of delivered hemodialysis treatment time. Hemodialysis International, 2006, 10, 346-350.	0.9	7
129	Provision and quality of dialysis services in <scp>L</scp> ibya. Hemodialysis International, 2011, 15, 444-452.	0.9	7
130	Regional Variation in Acute Kidney Injury Requiring Dialysis in the English National Health Service from 2000 to 2015 – A National Epidemiological Study. PLoS ONE, 2016, 11, e0162856.	2.5	7
131	Determinants of survival in patients receiving dialysis in L ibya. Hemodialysis International, 2013, 17, 249-255.	0.9	6
132	Chronic kidney disease in general populations and primary care. Current Opinion in Nephrology and Hypertension, 2013, 22, 593-598.	2.0	6
133	Helping people to live well with chronic kidney disease. British Journal of Hospital Medicine (London,) Tj ETQq1 1	0.784314	rgBT /Overlo
134	Sodiumâ€glucose linked transporterâ€2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk. Diabetes, Obesity and Metabolism, 2020, 22, 1024-1034.	4.4	6
135	Impact of Dietetic Intervention on Skin Autofluorescence and Nutritional Status in Persons Receiving Dialysis: A Proof of Principle Study. , 2020, 30, 540-547.		6
136	Change in glomerular filtration rate over time in the Oxford Renal Cohort Study: observational study. British Journal of General Practice, 2022, 72, e261-e268.	1.4	6
137	Chronic kidney disease 10 years on. Current Opinion in Nephrology and Hypertension, 2012, 21, 607-611.	2.0	5
138	Progress in risk prediction for people with chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2014, 23, 519-524.	2.0	5
139	Application of the Lomb-Scargle Periodogram to InvestigateHeart Rate Variability during Haemodialysis. Journal of Healthcare Engineering, 2020, 2020, 1-18.	1.9	5
140	Adaptation to Nephron Loss and Mechanisms of Progression in Chronic Kidney Disease. , 2011, , 1918-1971.		5
141	Hidden risks associated with conventional short intermittent hemodialysis: A call for action to mitigate cardiovascular risk and morbidity. World Journal of Nephrology, 2022, 11, 39-57.	2.0	5
142	Imaging and assessment of vascular calcification in chronic kidney disease patients. Current Opinion in Nephrology and Hypertension, 2004, 13, 637-640.	2.0	4
143	An unusual case of renovascular hypertension–renal artery stenosis of a pelvic kidney with aberrant blood supply. Nephrology Dialysis Transplantation, 2005, 20, 2861-2863.	0.7	4
144	Chronic kidney disease in older people – diagnosis, aetiology and consequences. Current Opinion in Nephrology and Hypertension, 2015, 24, 475-479.	2.0	4

#	Article	IF	CITATIONS
145	Development of a trigger tool to detect harm during haemodialysis. Journal of Kidney Care, 2016, 1, 72-77.	0.1	4
146	Nutritional status assessment: a neglected biomarker in persons with end-stage kidney disease. Current Opinion in Nephrology and Hypertension, 2020, 29, 547-554.	2.0	4
147	Biological variation of cardiac troponins in chronic kidney disease. Annals of Clinical Biochemistry, 2020, 57, 162-169.	1.6	4
148	Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: AÂcohort study. PLoS Medicine, 2020, 17, e1003050.	8.4	4
149	Determinants of change in arterial stiffness over 5 years in early chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 281-288.	0.7	4
150	Impact of malnutrition on health-related quality of life in persons receiving dialysis: a prospective study. British Journal of Nutrition, 2022, 127, 1647-1655.	2.3	4
151	An Analysis of Frequency of Continuous Blood Pressure Variation and Haemodynamic Responses during Haemodialysis. Blood Purification, 2022, 51, 435-449.	1.8	4
152	Risk Factors and Chronic Kidney Disease. , 2011, , 758-781.		4
153	What is the value of multidisciplinary care for chronic kidney disease?. PLoS Medicine, 2018, 15, e1002533.	8.4	4
154	Effect of weekend admission on mortality associated with severe acute kidney injury in England: A propensity score matched, population-based study. PLoS ONE, 2017, 12, e0186048.	2.5	4
155	Renal infarction in patients presenting with suspected renal colic. CKJ: Clinical Kidney Journal, 2009, 2, 362-364.	2.9	3
156	Where now for proteinuria testing in chronic kidney disease?: Good evidence can clarify a potentially confusing message. British Journal of General Practice, 2016, 66, 215-217.	1.4	3
157	OUP accepted manuscript. CKJ: Clinical Kidney Journal, 2021, 14, 1969-1976.	2.9	3
158	â€~l didn't have any option': experiences of people receiving in-centre haemodialysis during the COVID-19 pandemic. Journal of Kidney Care, 2022, 7, 112-119.	0.1	3
159	An unusual case of severe high anion gap metabolic acidosis. CKJ: Clinical Kidney Journal, 2011, 4, 90-92.	2.9	2
160	Vascular Access in Patients Receiving Hemodialysis in Libya. Journal of Vascular Access, 2012, 13, 468-474.	0.9	2
161	Personalized medicine in nephrology. Current Opinion in Nephrology and Hypertension, 2018, 27, 395-397.	2.0	2
162	An iterative run-to-run learning model to derive continuous brachial pressure estimates from arterial and venous lines during dialysis treatment. Biomedical Signal Processing and Control, 2021, 65, 102346.	5.7	2

#	Article	IF	CITATIONS
163	Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum. Rheumatology Advances in Practice, 2022, 6, .	0.7	2
164	Skin autofluorescence: a risk marker for chronic kidney disease. Journal of Renal Nursing, 2015, 7, 214-221.	0.1	1
165	The kidneys find a voice in cardiovascular risk prediction. Nature Reviews Nephrology, 2015, 11, 510-512.	9.6	1
166	FP351THE BURDEN AND SURVIVAL IMPLICATIONS OF COMORBIDITY IN PEOPLE WITH CHRONIC KIDNEY DISEASE STAGE 3. Nephrology Dialysis Transplantation, 2015, 30, iii185-iii186.	0.7	1
167	Development of a haemodialysis patient safety index. Journal of Kidney Care, 2018, 3, 96-101.	0.1	1
168	What every doctor needs to know about chronic kidney disease. British Journal of Hospital Medicine (London, England: 2005), 2018, 79, 438-443.	0.5	1
169	SP541MEASURING PRESSURE WAVES IN DIALYSIS LINES TO DERIVE CONTINUOUS ARTERIAL BLOOD PRESSURE: PILOT WORK IN AN IN VITRO AND IN SILICO MODEL. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	1
170	FP630DEVELOPMENT OF AN IN VITRO SIMULATION MODEL TO INVESTIGATE HAEMODYNAMIC RESPONSES DURING HAEMODIALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	1
171	A Paradigm to Discover Biomarkers Associated With Chronic Kidney Disease Progression. Biomarker Insights, 2020, 15, 117727192097614.	2.5	1
172	P1078IMPACT OF A MEDIUM CUT-OFF DIALYZER ON SKIN AUTOFLUORESCENCE IN HAEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
173	A Stepped Care Approach to the Management of Chronic Kidney Disease. , 2012, , 2205-2239.		1
174	Repeatability of Contrast-Enhanced Ultrasound to Determine Renal Cortical Perfusion. Diagnostics, 2022, 12, 1293.	2.6	1
175	Room for improvement: diagnosing and managing acute coronary syndromes in persons with reduced eGFR. Kidney International, 2022, 102, 20-22.	5.2	1
176	Adjustment and wellbeing among people with end-stage chronic kidney disease receiving in-centre haemodialysis during the COVID-19 pandemic. Journal of Kidney Care, 2022, 7, 70-79.	0.1	1
177	Diagnostics and techniques. Current Opinion in Nephrology and Hypertension, 2000, 9, 649-650.	2.0	Ο
178	Proteinuria: new information from an old friend. Current Opinion in Nephrology and Hypertension, 2003, 12, 615-617.	2.0	0
179	MO032CKD REMISSION IN A PROSPECTIVE COHORT OF PEOPLE WITH CKD STAGE 3 RECRUITED FROM PRIMARY CARE. Nephrology Dialysis Transplantation, 2016, 31, i41-i41.	0.7	0
180	SP279CHANGE IN SKIN AUTOFLOURESCENCE OVER ONE YEAR PREDICTS MORTALITY AT FIVE YEARS IN A PROSPECTIVE COHORT OF PEOPLE WITH CHRONIC KIDNEY DISEASE STAGE 3. Nephrology Dialysis Transplantation, 2016, 31, i180-i181.	0.7	0

#	Article	IF	CITATIONS
181	TO025RISK FACTORS FOR CKD PROGRESSION AFTER ACUTE KIDNEY INJURY. Nephrology Dialysis Transplantation, 2016, 31, i71-i72.	0.7	0
182	MP346VITAMIND DEFICIENCY AND ELEVATED PTH BUT NOT FGF-23 PREDICT ALL-CAUSE MORTALITY IN PEOPLE WITH CKD STAGE 3 IN PRIMARY CARE. Nephrology Dialysis Transplantation, 2016, 31, i454-i455.	0.7	0
183	UK Kidney Week 2016: innovation for better care. Journal of Kidney Care, 2016, 1, 78-80.	0.1	0
184	SP240PRESCRIBING PATTERNS AT THE TIME OF AKI: OPPORTUNITIES TO IMPROVE CARE. Nephrology Dialysis Transplantation, 2017, 32, iii186-iii186.	0.7	0
185	SP195EFFECT OF WEEKEND ADMISSION ON MORTALITY ASSOCIATED WITH SEVERE ACUTE KIDNEY INJURY IN ENGLAND: A PROPENSITY SCORE MATCHED, POPULATION-BASED STUDY. Nephrology Dialysis Transplantation, 2017, 32, iii169-iii169.	0.7	0
186	SP265ASSESSMENT OF CHRONIC KIDNEY DISEASE USING MULTI-PARAMETRIC MRI: REPRODUCIBILITY, CORRELATION WITH HISTOLOGY AND PROGRESSION. Nephrology Dialysis Transplantation, 2018, 33, i433-i433.	0.7	0
187	FP638FREQUENCY ANALYSIS REVEALS UNIQUE HAEMODYNAMIC RESPONSES TO HAEMODIALYSIS: BASELINE RESULTS FROM THE ITREND STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
188	Validation of the European Renal Best Practice guideline algorithm for management of older patients with advanced chronic kidney disease: a commentary. Nephrology Dialysis Transplantation, 2020, 35, 908-911.	0.7	0
189	The authors reply. Kidney International, 2020, 97, 616.	5.2	0
190	The authors reply. Kidney International, 2020, 97, 214-215.	5.2	0
191	How to Achieve Maximal Renoprotection in Non-Diabetic Chronic Renal Disease. , 2002, , 1-8.		0
192	The Impact of Donor Brain Death on Graft Integrity after Transplantation. Graft: Organ and Cell Transplantation, 0, 5, 164-166.	0.0	0
193	FP313DETERMINANTS OF CHANGE IN ARTERIAL STIFFNESS OVER 5 YEARS IN EARLY CKD. Nephrology Dialysis Transplantation, 2018, 33, i136-i137.	0.7	0
194	SP284HOSPITAL ADMISSIONS IN PERSONS WITH CHRONIC KIDNEY DISEASE STAGE 3. Nephrology Dialysis Transplantation, 2018, 33, i438-i439.	0.7	0
195	Title is missing!. , 2020, 17, e1003163.		0
196	Title is missing!. , 2020, 17, e1003163.		0
197	Title is missing!. , 2020, 17, e1003163.		0
198	Title is missing!. , 2020, 17, e1003163.		0

#	Article	IF	CITATIONS
199	Title is missing!. , 2020, 17, e1003163.		0
200	Title is missing!. , 2020, 17, e1003163.		0
201	Acute kidney injury associated with COVID-19: A retrospective cohort study. , 2020, 17, e1003406.		0
202	Acute kidney injury associated with COVID-19: A retrospective cohort study. , 2020, 17, e1003406.		0
203	Acute kidney injury associated with COVID-19: A retrospective cohort study. , 2020, 17, e1003406.		0
204	Acute kidney injury associated with COVID-19: A retrospective cohort study. , 2020, 17, e1003406.		0
205	Acute kidney injury associated with COVID-19: A retrospective cohort study. , 2020, 17, e1003406.		0
206	Title is missing!. , 2020, 17, e1003050.		0
207	Title is missing!. , 2020, 17, e1003050.		0
208	Title is missing!. , 2020, 17, e1003050.		0
209	Title is missing!. , 2020, 17, e1003050.		0
210	Title is missing!. , 2020, 17, e1003050.		0
211	Simple, high-throughput measurement of gut-derived short-chain fatty acids in clinically relevant biofluids using gas chromatography-mass spectrometry. Journal of Mass Spectrometry and Advances in the Clinical Lab, 2022, , .	2.4	0